Doer Biologics Closed nearly ¥100 Million Series A+ financing,

Zhejiang Doer Biologics announced that it had closed a ¥100 million Series A+ financing, co-invested by Sinowisdom, subsidiary of HY Energy anacea Venture, and Kaitai Capital,  and Hangzhou Bairui.  The Series A+ financing will be mainly used to promote the clinical application of the company's three first-class innovative drugs, as well as subsequent pipeline R&D and preclinical research.

Located in Hangzhou Economic and Technological Development Zone, Zhejiang Doer Biologics Corporation (Doer Biologics), is a research-based biopharmaceutical company with registered capital of 30 million CNY. Focusing on the discovery of protein drugs for metabolic diseases and cancers, Doer Biologics is recognized as a Hi-Tech enterprise by Hangzhou government and supported by "QINGLAN Projects" of Hangzhou city. 

Doer Biologics owns proprietary intellectual property rights of three protein drug discovery platforms: recombinant PEG-like xLONGylation®  platform, MultiBody® platform and AccuBody® platform.  

Doer Biologics comprises of young scientists and experienced experts in biologics. They are experts in molecular biology, cell culturing and fermentation, protein purification, bioassay,immunological analysis and animal experiments. Doer Biologics is endeavoring together to develop safer and more potent next-generation protein drugs for cancers and metabolic diseases, helping patients out of the tortures.